Procaspase-2 is one of the cysteine aspartate proteases involved in apoptotic cell death. Alternative splicing of CASP-2 messenger RNA generates a long isoform, procaspase-2L, whose overexpression induces cell death and a truncated isoform, procaspase-2S, whose function remains poorly de®ned. The present study explored the consequences of procaspase-2S overexpression in U937 human leukemic cells exposed to the topoisomerase II inhibitor etoposide as an apoptotic stimulus. Overexpression of procaspase-2S in U937 cells partially prevented nuclear changes associated with etoposideinduced cell death, as determined by Hoechst 33342 staining of nuclear chromatin and electron microscopy studies. Procaspase-2S also prevented the maturation of apoptotic bodies, delayed phosphatidylserine externalization on the plasma membrane and prevented the cleavage and activation of procaspase-2L. These eects were not observed when the cysteine 289 in the consensus QACRG motif was mutated into a serine. Wild-type procaspase-2S overexpression did not in¯uence the cleavage of procaspase-3, procaspase-7 and poly(ADPribose)polymerase nor the fragmentation of nuclear DNA into nucleosome-sized fragments. Altogether, these results indicate that the short isoform of procaspase-2 negatively interferes with selective features of apoptosis, an activity that is suppressed by mutation of the cysteine 289. Oncogene (2001) 20, 260 ± 269.
Introduction
Apoptosis has been initially described as a stereotyped sequence of structural changes that begin with the aggregation of the chromatin in large compact granular masses underlying the nuclear membrane, the condensation of the cytoplasm and the blebbing of the plasma membrane. At a later stage, the nucleus has usually broken up into a number of discrete fragments containing highly condensed chromatin while the overall compaction of the cytoplasm is associated with the appearance of translucent cytoplasmic vacuoles. Finally, the protuberances on the cell surface form membrane-bound apoptotic bodies of roughly spherical or ovoid shape and varying size, that contain cytoplasmic elements and/or highly condensed nuclear fragments. These apoptotic bodies, dispersed in intercellular tissue space, are recognized and engulfed by neighboring cells (Wyllie et al., 1980) , due to modi®cations in the plasma membrane structure, e.g. externalization of the negatively charge phosphatidylserine .
In many forms of apoptosis, dying cells activate a series of cysteine aspartic proteases known as caspases that ensure limited digestion of critical cellular components from the inside. Caspases are synthesized as inactive proenzymes, including an aminoterminal prodomain, a large subunit containing the consensus motif QACXG and a small subunit, that must be cleaved at key aspartate residues to be activated (Earnshaw et al., 1999) . Functional homologies led to distinguish the caspase-1 family (caspase-1, -4, -5, -11, -12 and -14) that is mainly involved in cytokine maturation, from the caspase-3 family (caspase-3, -6, -7, -8, -9, -10 ) that plays a central role in apoptosis. In this latter family, enzymes with a short prodomain (caspase-3, -6 and -7) were proposed to function as downstream eectors of a cascade in which enzymes with a long prodomain function as upstream signal transducers (Kumar, 1999) . Actually, studies performed in cell-free systems have shown that caspase-3 and -7 can cleave and activate caspases with a long prodomain (Slee et al., 1999; Van de Craen et al., 1999) .
Caspase-2 is a long prodomain containing enzyme that is activated in many cell types in response to various apoptotic stimuli (Wang et al., 1994) . Its prodomain is essential for oligomerization, autoactivation, nuclear migration and interaction with the adaptor molecule RAIDD (Duan and Dixit, 1997 ) also known as CRADD (Ahmad et al., 1997) . Alternative splicing of CASP-2 mRNA generates a long isoform, procaspase-2L, whose overexpression induces cell death, and a truncated isoform, procaspase-2S, that is devoid of the small subunit and was reported to antagonize cell death induced by serum withdrawal (Wang et al., 1994) . The dual eect of the enzyme was also suggested by analysis of caspase-2-de®cient mice (Bergeron et al., 1998) . The long isoform of procaspase-2 has been localized to the cytoplasm, the mitochondria, the Golgi complex and the nucleus (Colussi et al., 1998; Susin et al., 1999a; Mancini et al., 2000) . Interaction of its prodomain with the adaptor molecule RAIDD/CRADD could connect procaspase-2L to the tumor necrosis factor receptor (Duan and Dixit, 1997) . In a cell-free system, procaspase-2L is cleaved by eector caspases such as caspase-3, suggesting its possible involvement downstream in the caspase cascade (Slee et al., 1999; Van de Craen et al., 1999) . Upon apoptotic stimulation, procaspase-2L accumulates in the nucleus where it colocalizes with RAIDD/CRADD to dot-like and ®lamentous structures (Shearwin-Whyatt et al., 2000) and in the Golgi apparatus where it cleaves golgin-160 (Mancini et al., 2000) .
The role of the short isoform of procaspase-2 remains poorly understood. The present study tested the in¯uence of its overexpression in the U937 human leukemic cell line on the various apoptotic features induced by exposing these cells to the topoisomerase II inhibitor etoposide. Since the cysteine of the consensus motif QACXG is required for the proteolytic activity of caspases, we also studied whether mutation of the cysteine 289 in the QACRG sequence of procaspase-2S could modify the consequences of the protein overexpression.
Results

Transient transfection of CASP-2S inhibits the nuclear features of apoptosis in U937 cells
The human CASP-2S cDNAs encoding the wild-type isoform and the C289S mutant (Figure 1a ), cloned in pTarget vector, were transiently expressed in U937 cells, in combination with GFP-encoding cDNA. Forty-eight hours later, we measured the ability of etoposide (50 mM for 5 h) to induce apoptosis in GFP-positive cells. The nuclear features of apoptosis (chromatin condensation and nuclear fragmentation) were identi®ed by staining nuclear chromatin with Hoechst 33342. As indicated on Figure 1b and c, overexpression of CASP-2S delayed the appearance of apoptotic nuclear features in U937 cells exposed to etoposide. Similar results were obtained when the transiently transfected cells were exposed to anti-Fas mAbs (clone CH11 : 50 ng/ml+cycloheximide 0.8 mg/ ml) (data not shown). Interestingly, the C289S mutation suppressed the ability of wild-type caspase-2S to delay cell death-related nuclear changes in cells exposed to etoposide (Figure 1b and c) and anti-Fas Abs (not shown).
Stable overexpression of procaspase-2S modulates the morphological features of apoptosis in U937 cells
To further assess the role of procaspase-2S in apoptosis, wild-type and mutated CASP2S cDNAs were stably transfected in U937 cells. One clone transfected with the empty vector (U-Neo), one clone (U-WT1) and one mixed cell population (U-WT2) expression CASP2S cDNA, and two mixed populations expressing mutated CASP2S cDNA (U-Mut1 and U-Mut2) were selected for further experiments. PCR analysis of genomic DNA using primers recognizing vector polylinker sequences demonstrated the presence of the expressed cDNAs in CASP2S-transfected cells, not in U-Neo cells (Figure 2a) . Western blot analysis of the transfected cells using an anti-human caspase-2 mAb identi®ed a 48 kDa protein corresponding to procaspase-2L and a 35 kDa protein corresponding to procaspase-2S. This latter protein was overexpressed in cells transfected with CASP2S cDNAs (Figure 2b ). The ratio of caspase-2S to caspase-2L, as determined by scanning immunoblots, was at least ®vefold increased in stably transfected cells (U-WT1 :65; U-WT2 :611; U-Mut1 :614; U-Mut2 :68).
We explored the ability of etoposide to induce apoptosis-related morphological changes in the various populations of U937 cells. Ultrastructural analysis of these cells by electron microscopy, revealed impressive dierences. When U-Neo were treated with 50 mM etoposide for 5 h (Figure 3a) , they showed highly condensed chromatin into dense specks in shrinked cells and numerous vesicles of varying size and content, some of which being released to the extracellular space. In addition, U-Neo cells were fragmented into apoptotic bodies of varying size, some of them containing heavily condensed chromatin and vesicles. In contrast, when treated in the same conditions, cells overexpressing wild-type procaspase-2S (U-WT1 cells; Figure 3b ) were much less dismantled, with limited condensation of the chromatin localized around the nuclear envelope. Their nuclei appeared lobulated or fragmented while their cytoplasm contained much less vesicles than U-Neo cells. The most striking dierence between U-Neo and U-WT1 cells exposed to etoposide was the very low number of extracellular apoptotic bodies around cells overexpressing procaspase-2S. U937 cells transfected with the mutated CASP2S cDNA (U-Mut2) behave as U-Neo cells (Figure 3c ), indicating that the cysteine 289 was required for caspase-2S to interfere with nuclear features of apoptosis and the formation of apoptotic bodies.
To further analyse the eect of caspase-2S on the morphological changes associated with etoposide-induced apoptosis, we performed kinetic experiments in which morphological changes were identi®ed by combining phase contrast microscopy and nuclear chromatin staining with the Hoescht 33342 dye. By counting the number of cells with apoptotic morphology, based on the formation of chromatin dots, we observed that overexpression of wild-type procaspase-2S delayed chromatin condensation in U937 cells exposed to 50 mM etoposide, thus con®rming the results obtained in transiently transfected cells (Table 1 ). In addition, UNeo cells were rapidly and heavily dismantled with the formation of apoptotic bodies. After a 30-h exposure to the drug, virtually all U-Neo cells were fragmented ( Figure 4 ). In contrast, cells overexpressing procaspase-2S were much less disassembled, e.g. the extracellular . After a 30-h exposure to the drug, many U-WT1 cells demonstrated chromatin condensation without formation of apoptotic bodies. In these kinetic experiments, cells transfected with the C289S mutant behave as U-Neo cells, further suggesting that the cysteine 289 was required for the biological eects of caspase-2S. These morphological observations were con®rmed by using¯ow cytometry to monitor the size and granulation of the various cell populations when exposed to 50 mM etoposide for various times. Figure 5 shows that both the size and the granulation scatters decrease more rapidly in U-Neo and U-Mut2 cells than in U-WT1 cells.
Overexpression of procaspase-2S delays phosphatidylserine externalization in etoposide-treated U937 cells
Another marker of apoptosis is the externalization of phosphatidylserine on the outer lea¯et of the plasma membrane (Fadok et al., 1992) . Using FITC-labeled annexin V and propidium iodide labeling, we observed that etoposide-induced phosphatidylserine externalization was signi®cantly delayed in cells overexpressing wild-type procaspase-2S as compared to control U-Neo cells and cells expressing the C289S mutant. In all cases, most cells remained unlabeled by propidium iodide, indicating that the plasma membrane was not disrupted (Figure 6 ).
Overexpression of procaspase-2S does not prevent oligonucleosome-sized DNA fragmentation in etoposide-treated U937 cells
Another typical feature of etoposide-induced nuclear apoptosis in U937 cells is internucleosomal DNA fragmentation. By using a DNA ®lter elution assay to quantify DNA fragmentation, we observed that overexpression of either wild-type or mutated procaspase-2S had no signi®cant in¯uence on etoposideinduced DNA fragmentation (Figure 7a ). The speci®-city of DNA fragmentation monitored by the DNA ®lter elution assay was con®rmed by agarose gel electrophoresis where fragmented DNA was visualized as an oligonucleosome-sized DNA ladder (Figure 7b) . Again, overexpression of procaspase-2S appeared not to signi®cantly in¯uence the appearance of internucleosomal DNA fragmentation.
Overexpression of caspase-2S interferes with activation of caspase-2L
Exposure of U-Neo cells to 50 mM etoposide for 4.5 h induced the cleavage of the 32 kDa procaspase-3 and the 35 kDa procaspase-7 into their p19/p17 and p10 active fragments, respectively. This treatment also decreased procaspase-2L expression and induced the cleavage of the 116 kDa PARP into a 85 kDa Nterminal fragment (Figure 8 ). Meanwhile, we did not Table 1 Percentage of apoptotic cells after etoposide-treatment The ®ve cell populations were treated with 50 mM etoposide for indicated times. Apoptotic cells were identi®ed by¯uorescence microscopy after staining nuclear chromatin with Hoescht 33342. Each percentage is the mean+s.d. of three experiments with 300 cells counted at each timepoint Figure 4 Procaspase-2S overexpression modulates apoptosis related-morphological changes. U-Neo, U-WT1 and U-Mut2 cells were treated for indicated times with 50 mM etoposide (VP16). Then, the nuclear chromatin was stained with Hoechst 33342 for 30 min at 378C and morphological changes were examined bȳ uorescence and phase contrast microscopy (Magni®cation:640). Similar results were obtained by testing U-WT2 and U-Mut1 cells observed any cleavage of the 43 kDa actin nor any change in the expression of Bcl-2 and Bax. Overexpression of wild-type procaspase-2S prevented etoposide-induced decrease of procaspase-2L expression without modifying the changes in the expression of other studied caspases nor preventing PARP cleavage. The C289S mutation in procaspase-2S suppressed the ability of the protein to prevent the decrease of procaspase-2L expression observed in etoposide-treated cells (Figure 8 ). To con®rm this latter observation, we compared the in¯uence of 50 mM etoposide on procaspase-2L expression and z-VDVAD-AFC cleavage (that re¯ects caspase-2 activity) in the various cell clones and populations established for this study. We observed that procaspase-2S interfered with caspase-2L activation (as demonstrated by the delayed decrease in procaspase-2L expression and the delayed increase in z-VDVAD-AFC cleavage) in both U-WT1 clone and U-WT2 mixed population as compared to U-Neo cells. This negative in¯uence of procaspase-2S on caspase-2L activation was not observed when the mutated form (C289S) of procaspase-2S was overexpressed in U937 cells (U-Mut1 and U-Mut2 mixed cell populations) (Figure 9 ).
Discussion
A simple view of the caspase cascade that leads to cell death implicates enzymes with a long prodomain as initiators and those with a short prodomain as eectors of the cell demise. Actually, caspases with a short prodomain can transactivate caspases with a long prodomain, e.g. to realize ampli®cation pathways (Swanton et al., 1999; Slee et al., 1999) . In addition, several regulatory mechanisms that include transcriptional regulation of the enzymes (Droin et al., 1998; Kojima et al., 1998; Fujimura et al., 1999) , posttranslational modi®cations (Dimmeler et al., 1997; Cardone et al., 1998) , sub-cellular compartmentalization (Colussi et al., 1998; Susin et al., 1999a , Mancini et al., 2000 and interaction with adaptor or inhibitor molecules (for review: Kumar, 1999 ) modulate the caspase cascade. An additional level of complexity is the existence of alternative spliced isoforms described for several caspases, including caspase-1, -2, -6, -8, -9 and -10 ( Cohen, 1997; Srinivasula et al., 1999; Seol and Billiar, 1999; Ng et al., 1999) . Some of these isoforms are pro-apoptotic proteins, either due to intrinsic proteolytic activity or the presence of a death eector domain (DED) or a caspase recruitment domain (CARD) involved in the formation of an insoluble ®lamentous perinuclear structure (Ng et al., 1999) . In contrast, other caspase-isoforms are anti-apoptotic, e.g. a short isoform of caspase-9 interacts with the CARD of Apaf-1 and blocks the activation of procaspase-9 , 1999) . CASP-2S mRNA has been detected in all embryonic and adult tissues examined (Wang et al., 1994) . While its overexpression does not induce apoptosis, its ability to prevent cell death remains controversial (Wang et al., 1994; Kumar et al., 1997 , Ito et al., 2000 . Analysis of caspase-2-de®cient mice has identi®ed almost complete resistance of oocytes to apoptosis induced by a chemotherapeutic drug while the death of facial motor neurons was accelerated during mouse development, suggesting that a balance between the two caspase-2 isoforms could modulate its role in apoptosis of speci®c cell types (Bergeron et al., 1998) . Our data indicate that, when overexpressed in leukemic cells, procaspase-2S is an endogenous inhibitor of selective aspects of apoptosis, including externalization of phosphatidylserine on the plasma membrane, nuclear chromatin condensation and apoptotic body formation. Zhang et al. (1999) recently distinguished a partial condensation of chromatin, that was prevented by overexpressing the anti-apoptotic protein Bcl-2, from a complete condensation of chromatin, associated with the fragmentation of the nucleus, that was prevented by the caspase inhibitor z-DEVD-CH 2 F. The morphological features of procaspase-2S overexpressing cells exposed to etoposide suggested that this enzyme mostly delayed the ®nal condensation of the chromatin and the lobulation or fragmentation of the nucleus, also called karyorrhexis. Although partial chromatin condensation can occur in the absence of caspase activation, e.g. as a consequence of the mitochondrial release of the¯avoprotein apoptosis-inducing factor (AIF) (Susin et al., 1999b) or overexpression of the tumor-suppressor gene PML (Quignon et al., 1998) , several caspases usually contribute to this apoptotic feature, e.g. through the dismantling of nuclear proteins (Takahashi et al., 1996; Buendia et al., 1999) (Sahara et al., 1999) . Neither changes in Bcl-2 and Bax expression nor inhibition of caspase-3 nor caspase-7 activities could account for the eects of procaspase-2S on chromatin condensation. In contrast, procaspase-2S overexpression partially prevents caspase-2L activation, suggesting that this caspase, which has been localized partly in the nucleus (Colussi et al., 1998) , could play a role in initiating the condensation of nuclear chromatin. An alternative hypothesis is that procaspase-2S directly interferes with one or several of the other proteins that have been shown to play a role in chromatin condensation (Zamzami and Kroemer, 1999) .
At the end of the death process, apoptotic cells pinch o portions of themselves that contain membrane bound remnants including cellular organelles and chromatin fragments. The formation of these apoptotic bodies follows cell shrinkage and membrane blebbing, two consequences of ion eux (McCarthy and Cotter, 1997) . Its molecular mechanisms remain poorly understood, though caspase-3-mediated cleavage of p21-activated kinase 2 (PAK2) (Rudel and Bokoch, 1997) , actin/myosin II interactions and the Rho signaling (Mills et al., 1998) were involved in the process. After a 30-h exposure to 50 mM etoposide, virtually all the control U937 cells were fragmented into apoptotic bodies while a large number of procaspase-2S overexpressing cells were not fragmented, even when the chromatin was highly condensed and the nucleus fragmented. This observation suggests that overexpressed procaspase-2S interferes with the mechanisms involved in the appearance of these cellular corpses, e.g. by preventing the cleavage of a protein required for their formation or altering the mechanisms that control cell shrinkage. Overexpression of procaspase-2S substantially delayed the exposure of phosphatidylserine at the cell surface in response to etoposide exposure. The translocation of phosphatidylserine from the inner to the outer lea¯et of the cellular plasma membrane is an early sign of apoptosis that also plays a central role in the speci®c recognition of dead cells by neighboring phagocytes . The role of caspases in phosphatidylserine redistribution appears to depends on both the cell type and the stimulus (Rudel and Bokoch, 1997; Woo et al., 1998; Verhoven et al., 1999) . Other mechanisms involved in the loss of bilayer asymmetry include enhanced scramblase activity, decreased aminophospholipid translocase activity (Frasch et al., 2000) , increased activity of the serinebased exchange enzyme system (Pelassy et al., 2000) and increased calcium in¯ux across the plasma membrane (Verhoven et al., 1999) . The protein ISBP (for Ich-1S-binding protein), also known as CIB (for calcium and integrin-binding protein), was recently shown to interact with procaspase-2S (Ito et al., 2000) . Whether this protein, that shares homologies with calcineurin B and calmodulin, mediates the eects of procaspase-2S on phosphatidylserine externalization by modulating calcium transport remains to be determined.
Overexpression of procaspase-2S did not demonstrate any in¯uence on the fragmentation of nuclear DNA in oligonucleosome-sized fragments. One of the main nucleases involved in apoptotic DNA degradation is caspase-activated DNase (CAD) (Enari et al., 1998) that is complexed to its chaperone and inhibitor ICAD. In dying cells, ICAD is cleaved by caspases, mainly caspase-3, releasing the inhibition of CAD. CAD may be normally activated in procaspase-2S overexpressing cells, since caspase-3 cleavage is not altered in these cells. Thymocytes from mice in which a cleavage-resistant mutant of ICAD was expressed did not demonstrate DNA cleavage under apoptosis stimuli but exposed phosphatidylserine residues at their plasma membrane, clearly indicating that the two events are independent (McIlroy et al., 2000) . Our data demonstrate that chromatin condensation can also be partly dissociated from internucleosomal DNA Figure 9 Kinetics of caspase-2 expression and activity in etoposide-treated U937 cells. Procaspase-2L expression (immunoblots) and z-VDVAD-AFC (caspase-2L substrate) hydrolysis (histograms) were monitored in the ®ve studied cell clones or populations treated for indicated times with 50 mM etoposide. Results (mean+s.d. of triplicate measurements in a representative experiment) are activities in treated cells relative to control fragmentation and that procaspase-2S only interferes with the former event.
Overexpression of procaspase-2S in U937 cells speci®cally prevented the activation of caspase-2L without preventing caspase-3 and caspase-7 activation nor modulating the cleavage of PARP. Since caspase-2L was shown to be activated downstream of caspase-3 in a cell-free system (Slee et al., 1999) , procaspase-2S could directly interfere with caspase-2L activation, e.g. by competitively inhibiting prodomain-mediated homodimerization of procaspase-2L (Butt et al., 1998) or procaspase-2L / RAIDD interaction (Shearwin-Whyatt et al., 2000) . However, procaspase-2S failed to prevent apoptosis induced by overexpression of caspase-2L (Kumar et al., 1997) and recombinant procaspase-2S did not demonstrate any speci®c inhibitory eect towards caspase-2L in a cell-free system (unpublished data). Alternatively, the inhibitory eect of procaspase-2S could be mediated by the previously described ISBP that interacts with procaspase-2S and partially inhibits the processing of procaspase-2L in a cell-free system (Ito et al., 2000) .
The cysteine of the consensus QACXG motif is required for the proteolytic activity of every caspase (Nicholson, 1999) . The truncated procaspase-2S, that is devoid of the small subunit, contains a QACRG motif whose function remains unknown. Mutation of the cysteine 289 into a serine was observed to almost completely suppress the ability of procaspase-2S to prevent various features of etoposide-induced apoptosis. This cysteine is not included in the C-terminal, procaspase-2S-speci®c, 21 amino-acid sequence whose deletion (D292 ± 312) prevents procaspase-2S interaction with ISBP (Ito et al., 2000) . Thus, other consequences such as modi®cations of the topology of procaspase-2S (Nicholson, 1999) or its interaction with other cellular proteins might account for the strong in¯uence of this mutation on its biological properties.
In conclusion, overexpression of the short isoform of procaspase-2 in leukemic cells has impressive consequences on selective features of apoptosis. More speci®cally, procaspase-2S prevents complete nuclear disintegration, apoptotic body formation and phosphatidylserine externalization. Thus, procaspase-2S modulates the main events that cause neighboring cells to engulf the dying cells. Apoptotic bodies engulfment prevents the in¯ammatory response that is associated with necrosis (Ren and Savill, 1998) . Processing of phagocytosed apoptotic bodies has been shown also to yield antigens that access the cytosol and the MHC class I pathway of engul®ng cells (Albert et al., 1998) , can be recognized by antigen-speci®c lymphocytes (Ronchetti et al., 1999) and can induce dendritic cell maturation (Rovere et al., 1998) . The importance of apoptotic bodies for tumor cell immunogenicity (Bonnotte et al., 1998 (Bonnotte et al., , 2000 suggests that the procaspase-2S / procaspase-2L ratio, that is modulated by mammalian splicing factors (Jiang et al., 1998) , could determine the quality of a speci®c antitumor immune response.
Materials and methods
Cell culture, drug treatment and chemicals
The U937 human leukemia cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and was grown in RPMI-1640 medium supplemented with 10% (v/v) heat-inactived fetal calf serum and 2 mM Lglutamine in an atmosphere of 95% air and 5% CO 2 at 378C. All cell culture products were purchased from Biowhittaker (Fontenay-sous-bois, France). Etoposide was obtained from Sigma-Aldrich (Saint-Quentin Fallavier, France) and stock solution (50 mM) in dimethylsulfoxide was aliquoted and stored at 7808C. Further dilutions were made in culture medium prior to use. All other chemicals were of reagent grade and purchased from Sigma-Aldrich, ICN BioMedicals (Costa Mesa, CA, USA), Roche Molecular Biochemicals (Meylan, France) and local sources.
cDNA cloning and cell transfection
The human CASP-2S cDNA was obtained by RT ± PCR from U937 cell mRNA (Droin et al., 1998) and cloned in pTarget vector (Promega, CharbonnieÁ res, France). The sequence of the cDNA was checked to ®t with the published sequence for CASP2S (GenBank accession number: U13022). CASP-2s site-directed mutagenesis was performed by using a pTarget plasmid encoding the full length procaspase-2S. The couple of primers used to generate mutation of catalytic cysteine were primer sense 5'-ATGCATCCTCATCATCAG-GAA-3' and primer antisense 5'-CGGCCGCTCAGTGGT-GGTGGTGGTGGTGTAGAGCAAGAGAGGCGGTGGC-AGCAGTGAACAGAAGGAGGTGCCCAAGGGATCCA-ATAGCACCTCCACGGGAGGCCTG-3' containing the mutation and an His-tag. Transient transfections were performed using Superfect R transfection reagent (Qiagen SA, Courtaboeuf, France) by washing U937 cells in PBS, plating 7.5610 6 cells in 60-mm dishes and dissolving 5 mg of the tested plasmid combined with 5 mg of the Enhanced Green Fluorescent Protein plasmid (Clontech, Montigny le Bretonneux, France) in growth medium. Cells were incubated 10 min at room temperature with the plasmids in the presence of 20 ml of Superfect R reagent and were tested 48 h latter. Stable transfection was performed by electroporation of 10610 6 cells with 10 mg plasmid DNA and selection was done by culturing the cells for 4 weeks in the presence of 1 mg/ml geneticin (G418). Expression of the plasmid was monitored by PCR on genomic DNA using the universal sense primer T7 and the antisense primer 5'-CCCGGGGGTACCGTCGACTGCGGCCGC-3'. Ampli®ed DNA was analysed on 1.2% agarose gel stained with ethidium bromide.
Antibodies and caspase-2 substrate
The polyclonal rabbit anti-apopain antibody (Ab) that recognizes procaspase-3 and its p19 and p17 subunits was kindly provided by Dr D Nicholson (Merck, Toronto, Canada). The anti-procaspase-2 Ab (clone G310-1248) was obtained from Pharmingen (San Diego, CA, USA) and recognizes both procaspase-2L and procaspase-2S isoforms. Other Abs used were directed against human procaspase-7 (R&D System, Oxon, UK), procaspase-2L (sc-625) and Hsc70 (sc-7298) from SantaCruz (Santa Cruz, CA, USA), Bax (clone 4F11, Immunotech, Marseille, France), Bcl2 (Dako, Denmark), actin (clone 5F8, InnoGenex, San Ramon, CA, USA) and poly(ADP-ribose)polymerase (PARP) (Boeh-ringer Mannheim, Meylan, France). Goat horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PE, USA). Enhanced chemiluminescence reagents (ECL) were from Amersham. The caspase-2 substrate z-VDVAD-AFC (benzyloxycarbonyl-Valine-Aspartate-Valine-Alanine-Aspartate-7-amino-4-tri¯uoromethyl coumarin) was purchased from Calbiochem-Novabiochem Co (San Diego, CA, USA).
Identification of apoptosis
DNA fragmentation was measured by using a previously reported DNA ®lter elution assay (Bertrand et al., 1991) and expressed as percentage of fragmented relative to total DNA. DNA fragmentation was also visualized by extracting total DNA by a salting-out procedure (Miller et al., 1988) , then performing DNA electrophoresis in 1.8% agarose gel in Trisborate-EDTA buer (pH 8.0) followed by ethidium bromide staining. The nuclear chromatin was stained with Hoechst 33342 for 30 min at 378C for identifying morphological changes by¯uorescence microscopy. For electron microscopy, cell ®xation was performed in 0.1 M Milonig's phosphate buer (pH 7.4) containing 2.5% glutaraldehyde. Then, cells were stained with 2% uranyl acetate and dehydrated by repeated ethanol treatments. Sections (500 ± 700A) were stained in lead citrate and examined by transmission electron microscopy using a Ziess Em 10 CA microscope (JFE Enterprises, Brookville, MD, USA). Flow cytometry monitory of size and granulation was performed by using a FACScan apparatus (Becton Dickinson, Grenoble, France). Exposure of phosphatidylserine on the outer plasma membrane lea¯et was identi®ed by Annexin V-FITC staining in the presence of propidium iodide (Immunotech, Marseille, France) as described (Vermes et al., 1995) . Brie¯y, cells were resuspended in 10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl 2 , in the presence of annexin V-FITC (1.0 mg/ ml) and propidium iodide (1.0 mg/ml) for 10 min in the dark and analysed by using a FACScan¯ow cytometer.
Western blots
For Western blot analyses, cells were washed twice in PBS, lysed for 30 min in RIPA buer (150 mM NaCl, 50 mM TrisHCl, pH 8.0, 0.1% Na-SDS, 0.5% Na-desoxycholate) in the presence of protease inhibitors (0.1 mM PMSF, 2.5 mg/ml pepstatin, 10 mg/ml aprotinin, 2.5 mg/ml trypsin inhibitor, 5 mg/ml leupeptin), then centrifuged at 15 000 g for 20 min at 48C. Supernatants were collected and 50 mg proteins were incubated in loading buer (125 mM Tris-HCl, pH 6.8, 10% bmercaptoethanol, 4.6% SDS, 20% glycerol and 0.003% bromophenol blue) prior to SDS ± PAGE on a 12 ± 15% sodium dodecyl sulfate polyacrylamide gel. Following electrophoresis, proteins were electroblotted on PVDF membrane (Biorad, Yvry-sur-Seine, France). After blocking non-speci®c binding sites overnight with 5% nonfat milk in TPBS (PBS, 0.1% Tween 20), membranes were incubated for 2 ± 3 h at RT with the primary Abs. After three washes in TPBS, membranes were incubated with the corresponding peroxidase-conjugated secondary Abs for 30 min at RT. Immunoblots were revealed by ECL and autoradiography. For PARP cleavage analysis, cells were lysed in boiling lysis solution (1% SDS, 1 mmol/l Navanadate, 10 mmol/l Tris pH 7.4).
Caspase-2 activity
Cells were homogenized at 48C for 30 min in a lysis buer containing (100 mM HEPES (pH 7.5), 5 mM EDTA, 5 mM DTT, 20%, 0.3% NP-40), centrifuged at 10 000 g for 15 min at 48C and supernatants were collected and frozen at 7808C. Fifty mg of proteins were used to measure caspase-2 activity. Fluorescence was monitored continuously in a dual luminescence¯uorimeter (LS 50B Perkin Elmer) using excitation (400 nm) and emission (505 nm) wavelengths speci®c for caspase-2 substrate. Reactions were carried out at 378C using a water-jacketed sample compartment. The assay mixture contained 100 mM HEPES (pH 7.5), 20% glycerol, 5 mM DTT, 5 mM EDTA, 50 mM¯uorogenic peptides and 50 mg proteins per assay. Enzyme activities were determined as initial velocities and expressed as relative intensity/min/mg (Schmitt et al., 1998) .
Abbreviations AIF, apoptosis-inducing factor; CAD, caspase-activated DNAse; CARD, caspase recrutment domain; CRADD, caspase and RIP adaptator with death domain; ICAD, inhibitor of CAD; PCR, polymerase chain reaction, RAIDD, RIP-associated ICH-1/CED-3-homologous protein with a death domain. z-VDVAD-AFC: benzyloxycarbonyl-Valine-Aspartate-Valine-Alanine-Aspartate-7-amino-4-tri¯uoromethyl coumarin)
